MarketPeel
Insider Trading Intelligence
NW

Nadia Waheed

OCUL
CHIEF MEDICAL OFFICER · OCULAR THERAPEUTIX, INC · CIK 0002023884
FILING MIX · LIFETIME67%/33%
BUYS
8
SELLS
4
TOTAL VALUE
$332.5K
COMPANIES
1
ACTIVE SINCE
Jun 2024
HOLDINGS NOW
300,079
AVG SELL PX
$8.30
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Nadia Waheed, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%+0.75%+0.38%+0.37%+8.56%
14d3+0.00%+15.25%+0.13%+15.12%+6.21%
30d3+33.33%+5.82%-1.01%+6.83%+9.05%
60d3+33.33%+21.52%+2.58%+18.95%+17.67%
90d3+0.00%+18.59%+8.89%+17.38%+17.38%
180d3(2 pending)+0.00%+49.81%+15.30%+34.52%+34.52%
1y3(2 pending)+0.00%+11.10%
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OCUL · 300,079 shares · as of Jun 3, 2026
0106,250212,500318,750425,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 8 buys / 4 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
14,828$8.27$122.6K300,079Jun 3, 2026Jun 5, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
3,510$7.74$27.2K314,907Feb 20, 2026Feb 24, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
7,863$9.04$71.1K318,417Feb 12, 2026Feb 17, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
79,112326,280Jan 2, 2026Jan 6, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
240,932240,932Jan 2, 2026Jan 6, 2026View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
40,363247,168Aug 12, 2025Aug 14, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
122,923122,923Aug 12, 2025Aug 14, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
SALE10b5-1
10b5-1 plan
13,861$8.05$111.6K206,805Jun 2, 2025Jun 3, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
79,000220,666Feb 11, 2025Feb 13, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
237,000237,000Feb 11, 2025Feb 13, 2025View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
141,666141,666Jun 1, 2024Jun 4, 2024View →
OCUL
OCULAR THERAPEUTIX, INC
PURCHASEGRANT
Stock grant
425,000425,000Jun 1, 2024Jun 4, 2024View →
Other insiders · OCUL
Loading peer insiders…
About this filer
CIK 0002023884
ROLE
Chief Medical Officer
PRIMARY
OCUL
COMPANIES
1
ACTIVE SINCE
Jun 2024
MARKETPEEL · /INSIDER/0002023884DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback